Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

The instances of ARIA were primarily seen in participants treated with AL002. “We, at Alector, recognize the importance of ...

Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.

Alector is preparing to release phase 2 INVOKE-2 data for AL002, a candidate targeting TREM2, which has shown potential in earlier trials. The interest in TREM2 therapies has been bolstered by ...

In October 2024, Alector published a manuscript titled “Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease” in Alzheimer’s ...

Alector said AbbVie remains on board with AL002, a drug targeting TREM2 that comes with a $250 million option fee and around $243 million in milestones. That is further ahead in development ...

Ph.D., Chief Executive Officer of Alector. “We believe that increased TREM2 signaling via AL002 may recruit disease-fighting microglia to broadly counteract the progression of Alzheimer’s disease.

M.D., Chief Financial Officer of Alector. “We anticipate transformational data from both the AL002 INVOKE-2 Phase 2 trial and the latozinemab INFRONT-3 pivotal Phase 3 trial within our runway.

Under an agreement signed in 2017 AbbVie has an exclusive option to global development and marketing for AL003 and Alector’s TREM2 targeting monoclonal antibody, AL002. Alector will design and ...

This funding boosts its financial flexibility, allowing Alector to advance its pipeline, including the AL002 INVOKE-2 Phase 2 and latozinemab INFRONT-3 Phase 3 trials, and its innovative blood ...

Ph.D., Chief Executive Officer of Alector. “We believe that increased TREM2 signaling via AL002 may recruit disease-fighting microglia to broadly counteract the progression of Alzheimer’s disease.